Enable Injections said today that it inked development deals with Apellis Pharmaceuticals and UCB for its enFuse on-body drug-delivery device.
The Cincinnati-based company has ongoing partnerships with five companies. Enable Injection’s enFuse device is designed for the subcutaneous delivery of high-volume drugs, including monoclonal antibodies.
“Because enFuse frees patients to self-administer at home, it greatly enhances patient experience and overall patient value,” Jeff Wren, head of UCB’s neurology patient value unit, said in prepared remarks. “enFuse is the right answer for patient needs, which makes it a great addition to our program.”
“We are conducting human clinical trials using the enFuse technology to deliver our novel complement immunotherapies subcutaneously,” Dr. Cedric Francois, co-founder & CEO of Apellis, added. “With our broad therapeutic application, we are excited to partner with Enable to bring promising new therapies with a more patient-centric drug delivery system to patients in need.”
“Pharmaceutical companies racing to improve outcomes and be recognized as patient-centric are realizing the symbiosis between drug and delivery,” Enable Injection’s president & CEO, Michael Hooven, said. “They are partnering with Enable Injections to improve the patient experience, with the aim of increasing adherence and achieving the outcomes necessary for commercial success.”
Last month, Enable Injections closed a $50 million Series B round, led by Sanofi (NYSE:SNY). Previous investors, including the Cleveland Clinic and CincyTech, and private investors also participated in the round.
